Fact based stock research
Henan Taloph Pharmaceutical (SHSE:600222)
CNE0000010L8
Research has been discontinued. Contact us if you want research on this stock.
Henan Taloph Pharmaceutical stock research in summary
There is no stock research analysis by the purely financial fact-based Obermatt method for: Henan Taloph Pharmaceutical (SHSE:600222), Pharmaceuticals, China. Contact us if you would like research on this stock.
Latest Obermatt Ranks
Value Rank | n/a | |
Growth Rank | n/a | |
Safety Rank | n/a | |
Combined Rank | n/a |
Country | China |
Industry | Pharmaceuticals |
Index | |
Size class | Small |
January 1, 2000. Stock data may be delayed. Login to get the most recent research.
Research History: Henan Taloph Pharmaceutical
RESEARCH HISTORY | 2019 | 2020 | 2021 | 2022 | ||||
---|---|---|---|---|---|---|---|---|
VALUE | ||||||||
VALUE | n/a |
|
n/a |
|
n/a |
|
n/a |
|
GROWTH | ||||||||
GROWTH | n/a |
|
n/a |
|
n/a |
|
n/a |
|
SAFETY | ||||||||
SAFETY | n/a |
|
n/a |
|
n/a |
|
n/a |
|
COMBINED | ||||||||
COMBINED | n/a |
|
n/a |
|
n/a |
|
n/a |
|
Value Metrics in Detail
VALUE METRICS | 2019 | 2020 | 2021 | 2022 | ||||
---|---|---|---|---|---|---|---|---|
PRICE VS. REVENUES (P/S) | ||||||||
PRICE VS. REVENUES (P/S) | n/a |
|
n/a |
|
n/a |
|
n/a |
|
PRICE VS. PROFITS (P/E) | ||||||||
PRICE VS. PROFITS (P/E) | n/a |
|
n/a |
|
n/a |
|
n/a |
|
PRICE VS. CAPITAL (Market-to-Book) | ||||||||
PRICE VS. CAPITAL (Market-to-Book) | n/a |
|
n/a |
|
n/a |
|
n/a |
|
DIVIDEND YIELD | ||||||||
DIVIDEND YIELD | n/a |
|
n/a |
|
n/a |
|
n/a |
|
CONSOLIDATED RANK: VALUE | ||||||||
CONSOLIDATED RANK: VALUE | n/a |
|
n/a |
|
n/a |
|
n/a |
|
Growth Metrics in Detail
GROWTH METRICS | 2019 | 2020 | 2021 | 2022 | ||||
---|---|---|---|---|---|---|---|---|
REVENUE GROWTH | ||||||||
REVENUE GROWTH | n/a |
|
n/a |
|
n/a |
|
n/a |
|
PROFIT GROWTH | ||||||||
PROFIT GROWTH | n/a |
|
n/a |
|
n/a |
|
n/a |
|
STOCK RETURNS | ||||||||
STOCK RETURNS | n/a |
|
n/a |
|
n/a |
|
n/a |
|
CONSOLIDATED RANK: GROWTH | ||||||||
CONSOLIDATED RANK: GROWTH | n/a |
|
n/a |
|
n/a |
|
n/a |
|
Safety Metrics in Detail
SAFETY METRICS | 2019 | 2020 | 2021 | 2022 | ||||
---|---|---|---|---|---|---|---|---|
LEVERAGE | ||||||||
LEVERAGE | n/a |
|
n/a |
|
n/a |
|
n/a |
|
REFINANCING | ||||||||
REFINANCING | n/a |
|
n/a |
|
n/a |
|
n/a |
|
LIQUIDITY | ||||||||
LIQUIDITY | n/a |
|
n/a |
|
n/a |
|
n/a |
|
CONSOLIDATED RANK: SAFETY | ||||||||
CONSOLIDATED RANK: SAFETY | n/a |
|
n/a |
|
n/a |
|
n/a |
|
Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Henan Taloph Pharmaceutical from January 1, 2000.
We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.